Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
Malaysia Aviation Group to Buy Airbus SAE Unit 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
WordPress Malware Uses Ethereum to Evade Removal 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
Add as a preferred source on Google
BRIDGEWATER, N.J., May 08, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that the Company is scheduled to present at the 18th Annual B. Riley Co. Investor Conference.
| Event: | 18th Annual B. Riley Co. Investor Conference |
| Format: | Presentation and One-on-One Meetings |
| Date: | Wednesday, May 24, 2017 |
| Time: | 1:00pm PT |
| Location: | Santa Monica, CA |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group 646-536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group 508-280-6592 [email protected]
